EMERYVILLE, Calif. , June 11, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that, based on the preliminary vote count provided by its proxy solicitor following the Company's 2025 Annual Meeting of Stockholders ("Annual Meeting"), Dynavax stockholders have voted... Read More

Dynavax's Strategy is Delivering Significant Long-Term Stockholder Value Dynavax's Nominees Are Vastly Superior to Deep Track's Candidates Across Every Critical Area Follow Recommendations of Proxy Advisory Firms ISS and Egan-Jones and Vote "FOR" All Four of Dynavax's Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif. , June 9, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or... Read More

Dynavax is Already Delivering Significant Long Term Stockholder Value Through Execution of Current Strategy Overseen by Board; Deep Track's Inferior Short-Term Plan and Nominees are Not in the Best Interests of All Stockholders Glass Lewis' Recommendation Recognizes the Significant Stockholder Value Creation and Differentiated Capital Return Overseen by the Dynavax Board Reiterates ISS and Egan Jones Recommendations that... Read More

Glass Lewis Recommends Shareholders Vote FOR Deep Track Nominees Brett Erkman and Donald Santel and AGAINST Chairman Scott Myers and Director Brent MacGregor Notes that “Deep Track has Highlighted Valid and Critical Questions Regarding Dynavax’s Strategic Direction, Capital Allocation, and Board Responsiveness” Agrees that “Dynavax’s Current Capital Allocation Approach Appears Excessively Conservative” Deep Track Urges... Read More

EMERYVILLE, Calif. , May 28, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at William Blair's 45th Annual Growth Stock Conference on Tuesday, June 3rd at 2:40 p.m. CT . The presentations will be webcast and may be accessed through the "Events & Presentations"... Read More

ISS Recognizes There is No Case for Change Dynavax's Superior Strategy and Current Board are Best Equipped to Deliver Significant Long-Term Stockholder Value Dynavax Comments on Deep Track's Misleading Supplemental Materials Urges Stockholders to Follow ISS Recommendation and Vote "FOR" ALL Four of Dynavax's Highly Qualified Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif. , May 23, 2025 /PRNewswire/ --... Read More

Presentation Underscores Deep Track's Value Destructive Plan and Inferior Slate of Director Nominees Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif. , May 12, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today... Read More

In the news release, Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum, issued 07-May-2025 by Dynavax Technologies over PR Newswire, we are advised by the company that the second paragraph, second sentence of the stockholder letter should read "Dynavax has generated over $900 million of stockholder value, returning over 62% versus the S&P Biotechnology... Read More

Deep Track's Misleading Investor Presentation Demonstrates its Single-Minded Approach to Abandon Long-Term Value Opportunities in Exchange for Short-Term Return Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif. , May 7, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical... Read More

Record HEPLISAV-B® first quarter net product revenue of $65 million , representing 36% year-over-year growth Top-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in Q3 2025 New pandemic influenza adjuvant program and Lyme disease vaccine programs planned to enter clinical development in 2025 and 2027, respectively Conference call today at 4:30 p.m. ET / 1:30 p.m. PT EMERYVILLE, Calif. , May 6, 2025... Read More

Over half of American adults do not know chronic hepatitis B can cause liver disease such as cirrhosis and liver cancer Half of American adults were unaware that anyone can be at risk for the hepatitis B virus Findings released during Hepatitis Awareness Month underscore the importance of public education to address misunderstandings about hepatitis B and raise awareness of the Centers for Disease Control and Prevention... Read More

Mails Letter to Stockholders Urging Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card EMERYVILLE, Calif. , April 29, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today mailed a letter to its stockholders in connection with its 2025 Annual... Read More

EMERYVILLE, Calif. , April 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2025 financial results on Tuesday, May 6, 2025 , after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Tuesday, May 6, 2025 , at 4:30 p.m. ET / 1:30 p.m. PT... Read More

Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Highlights Record Financial and Operational Results, Balanced Capital Allocation Strategy and Meaningful Board Refreshment Underscores Deep Track's Value Destructive, Short-Term Focus and Unnecessary Proxy Contest EMERYVILLE, Calif. , April 17, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the... Read More

Dynavax's Board is Overseeing Record Operational and Financial Performance Outlines Extensive Engagement with Deep Track and Multiple Attempts to Reach a Resolution EMERYVILLE, Calif. , April 3, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today filed its preliminary proxy... Read More

Opportunistic refinancing extends the maturity of most of existing debt with improved terms and reduces dilution to existing capital structure $225 million of convertible notes due in 2030 issued, including an exchange for the retirement of ~$185 million of existing convertible notes due in 2026 and ~$40 million of new money Dynavax repurchased ~$8 million of the Company's common stock in connection with this transaction... Read More

EMERYVILLE, Calif. , Feb. 25, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in the following upcoming investor conferences: TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 1:10 p.m. ET Barclays 27th Annual Global Healthcare Conference on... Read More

HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million ; net product revenue expected to be $305 to $325 million in 2025 Top-line results in Phase 1/2 shingles trial expected in Q3 2025 Plan to initiate Phase 2 trial for plague vaccine in Q3 2025 Expect completion of $200 million share repurchase program in 2025 Conference call today at 4:30 p.m. ET / 1:30 p.m. PT EMERYVILLE, Calif. , Feb. 20, 2025... Read More

Reiterates Meaningful Board Change Already Underway EMERYVILLE, Calif. , Feb. 19, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued a statement underscoring continued execution momentum and commitment to driving long-term stockholder value. The Company also confirmed... Read More

EMERYVILLE, Calif. , Feb. 6, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025 , after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Thursday, February 20, 2025 , at... Read More

Appoints Emilio Emini and Lauren Silvernail to Board of Directors; Two Directors to Step Down at 2025 Annual Meeting Intends to Seek Stockholder Approval for Declassification of Board at 2025 Annual Meeting EMERYVILLE, Calif. , Jan. 27, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) (the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today... Read More

Preliminary 2024 HEPLISAV-B® net product revenue grew 26% year-over-year to approximately $268 million Enrollment completed in Phase 1/2 shingles trial; top line results expected in Q3 2025 New $30 million contract with U.S. Department of Defense to advance plague vaccine program Cash, cash equivalents and marketable securities were approximately $714 million as of December 31, 2024 EMERYVILLE, Calif. , Jan. 13, 2025... Read More

EMERYVILLE, Calif. , Nov. 26, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3 at 2:35 p.m. ET . The presentation will be webcast and may be accessed through the "Events & Presentations" page... Read More

EMERYVILLE, Calif. , Nov. 11, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that it has entered into an Accelerated Share Repurchase transaction ("ASR") under an agreement with Goldman Sachs & Co. LLC to repurchase $100 million of the Company's common stock. Dynavax executed the ASR as part... Read More

HEPLISAV-B® quarterly net product revenue of $79.3 million , representing 27% year-over-year growth Hepatitis B adult vaccine market expected to expand to a peak of over $900 million by 2030, with HEPLISAV-B expected to achieve at least 60% estimated total market share Expect positive net income in 2024, achieving full year profitability Strengthened cash position to $764 million in Q3'24 $200 million share repurchase... Read More

EMERYVILLE, Calif. , Nov. 7, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced its Board of Directors has authorized the repurchase of up to $200 million of the Company's common stock. The share repurchase program does not have an expiration date and Dynavax currently expects that purchases... Read More

EMERYVILLE, Calif. , Oct. 29, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that its Board of Directors has adopted a limited-duration stockholder rights plan, effective immediately (the "Rights Plan"). The Dynavax Board adopted the Rights Plan in response to the recent rapid accumulations... Read More

EMERYVILLE, Calif. , Oct. 24, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter 2024 financial results on Thursday, November 7, 2024 , after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Thursday, November 7, 2024 , at 4:30 p.m. ET /... Read More

Achieved record quarterly HEPLISAV-B® net product revenue of $70.2 million , growing 24% year-over-year Reaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 million Initiated dosing in Phase 1/2 trial of novel shingles vaccine program with clinical data expected in 2H 2025 Conference call today at 4:30 p.m. ET / 1:30 p.m. PT EMERYVILLE, Calif. , Aug. 6, 2024 /PRNewswire/ -- Dynavax Technologies... Read More

EMERYVILLE, Calif. , July 23, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter 2024 financial results on Tuesday, August 6, 2024 , after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Tuesday, August 6, 2024 , at 4:30 p.m. ET / 1:30... Read More

EMERYVILLE, Calif. , June 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the first participant has been dosed in a Phase 1/2 clinical trial evaluating the safety, tolerability, and immunogenicity of Z-1018, the company's investigational vaccine candidate being developed for the... Read More

EMERYVILLE, Calif. , May 28, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the following upcoming investor conferences during the month of June: William Blair 44 th Annual Growth Stock Conference on Tuesday, June 4 at 1:20 p.m. CT Goldman Sachs 45 th Annual... Read More

EMERYVILLE, Calif. , May 14, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today provided a regulatory update for the Company's supplemental Biologics License Application (sBLA) to include a four-dose HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted] regimen for adults on hemodialysis. The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) in response... Read More

HEPLISAV-B® vaccine net product revenue grew 10% year-over-year to approximately $48 million in the first quarter of 2024 Reaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 million Announces U.S. FDA clearance of IND application to initiate Phase 1/2 trial of Z-1018 shingles program Conference call today at 4:30 p.m. ET/ 1:30 p.m. PT EMERYVILLE, Calif. , May 8, 2024 /PRNewswire/ -- Dynavax... Read More

EMERYVILLE, Calif. , April 24, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2024 financial results on Wednesday, May 8, 2024 , after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Wednesday, May 8, 2024 , at 4:30 p.m. ET / 1:30... Read More

EMERYVILLE, Calif. , Feb. 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at TD Cowen's 44th Annual Health Care Conference on Monday, March 4 at 10:30 a.m. ET . The presentation will be webcast and may be accessed through the "Events & Presentations" page on... Read More

HEPLISAV-B® 2023 net product revenue grew 69% year-over-year to $213 million Achieved market leader status in key segments retail pharmacy and IDNs in 2023 2024 HEPLISAV-B net product revenue expected to be $265 - $280 million Cash position increased to $742 million at year end and expect to be cash flow positive for full year 2024 Conference call today at 4:30 p.m. ET / 1:30 p.m. PT EMERYVILLE, Calif. , Feb. 22, 2024... Read More

EMERYVILLE, Calif. , Feb. 8, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report fourth quarter and full year 2023 financial results on Thursday, February 22, 2024 , after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Thursday, February 22, 2024 , at... Read More

Preliminary full year 2023 HEPLISAV-B® vaccine net product revenue of approximately $213 million , a 69% year-over-year increase Significant gains in HEPLISAV-B market share in key market segments, with total U.S. market share increasing to approximately 44% compared to approximately 35% at the end of 2022 Strengthened financial position with cash, cash equivalents and marketable securities at year end increasing to... Read More

EMERYVILLE, Calif. , Jan. 3, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11 at 11:15 a.m. PT . The presentation will be webcast and may be accessed through the "Events & Presentations"... Read More

EMERYVILLE, Calif. , Nov. 20, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28 at 4:40 p.m. ET . The presentation will be webcast and may be accessed through the "Events & Presentations"... Read More

Generated quarterly HEPLISAV-B® vaccine net product revenue of $62.3 million , a 66% year-over-year increase Raising full year HEPLISAV-B net product revenue guidance to $210 - $220 million , compared to prior range of $200 - $215 million Cash and investments increased to $720 million at quarter end; expects positive free cash flow for full year Conference call today at 4:30 p.m. ET / 1:30 p.m. PT EMERYVILLE, Calif. , Nov.... Read More

EMERYVILLE, Calif. , Oct. 26, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter 2023 financial results on Thursday, November 2, 2023 , after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Thursday, November 2, 2023 , at 4:30 p.m. ET /... Read More

EMERYVILLE, Calif. , Oct. 19, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present the H.C. Wainwright 4th Annual Hepatitis B Virus Virtual Conference on Wednesday, October 25 at 1:00 p.m. ET . The presentation will be webcast and may be accessed through the "Events &... Read More

EMERYVILLE, Calif. , Sept. 6, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, September 13 at 12:00 p.m. ET . The fireside chat will be webcast and may be... Read More

Generated record quarterly HEPLISAV-B® vaccine net product revenue of $56 million , a 73% year-over-year increase Full year HEPLISAV-B net product revenue guidance raised to $200 - $215 million , compared to prior range of $165 - $185 million Cash and investments increased to $682 million at quarter end; expects positive free cash flow for full year Conference call today at 4:30 p.m. ET / 1:30 p.m. PT EMERYVILLE, Calif. ,... Read More

EMERYVILLE, Calif. , July 20, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter 2023 financial results on Thursday, August 3, 2023 , after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Thursday, August 3, 2023 , at 4:30 p.m. ET / 1:30... Read More

EMERYVILLE, Calif. , May 30, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the following upcoming investor conferences during the month of June: William Blair 43 rd Annual Growth Stock Conference on Tuesday, June 6 at 9:20 a.m. CT Goldman Sachs 44 th Annual... Read More

EMERYVILLE, Calif. , May 8, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the JMP Securities Life Sciences Conference on Monday, May 15 , at 1:00 p.m. E.T. The presentation will be webcast and may be accessed through the "Events &... Read More

HEPLISAV-B® vaccine net product revenue increased 109% year-over-year to $43.5 million in the first quarter of 2023 Reaffirming HEPLISAV-B net product revenue guidance for full year 2023 of between $165–$185 million, representing annual revenue growth of 30-47% Strengthened balance sheet with cash and investments of $652 million at quarter end and expects positive free cash flow in 2023 Conference call today at 4:30 p.m. ET... Read More

EMERYVILLE, Calif. , April 18, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2023 financial results on Tuesday, May 2, 2023 , after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Tuesday, May 2, 2023 , at 4:30 p.m. ET / 1:30 p.m. PT... Read More

EMERYVILLE, Calif. , March 1, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Kelly MacDonald , Chief Financial Officer, will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8 , at 2:10 p.m. E.T. The presentation will be webcast and may... Read More

HEPLISAV B is the only two-dose adult hepatitis B vaccine offering protection in just one month EMERYVILLE, Calif. , Feb. 28, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing innovative vaccines, today announced that the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorization in... Read More

2022 total revenue of $723 million , up 64% from $439 million in 2021 HEPLISAV-B ® vaccine net product revenue of $126 million , representing 104% growth compared to 2021 CpG 1018 ® adjuvant vaccine net product revenue of $588 million 2023 HEPLISAV-B net product revenue anticipated to be between $165 million and $185 million , representing year-over-year revenue growth of approximately 30-47% Increased strength of financial... Read More

EMERYVILLE, Calif. , Feb. 9, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report fourth quarter and full year 2022 financial results on Thursday, February 23, 2023 , after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Thursday, February 23, 2023 , at... Read More

EMERYVILLE, Calif. , Jan. 31, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, today announced that effective as of market open today, January 31, 2023 , its common stock has been approved for uplisting to the Nasdaq Global Select Market® and will continue trading under its current ticker symbol... Read More

China commercial launch in multiple provinces and municipalities expected to begin in Q1 2023, and Clover anticipates a significant and sustained long-term annual booster market for its premium, broadly protective protein-based COVID-19 vaccines in China SCB-2019 (CpG 1018/Alum) anticipated to receive emergency use authorization (EUA) in at least one additional country and to complete multiple EUA submissions during H1 2023,... Read More

Preliminary full year 2022 HEPLISAV-B ® vaccine Net Product Revenue of approximately $126 million , representing 104% growth compared to 2021 Preliminary full year CpG 1018 ® adjuvant Net Product Revenue of approximately $588 million Maintained strong financial position with year-end cash and investments of approximately $624 million Phase 1 shingles trial results demonstrate favorable tolerability with similar vaccine... Read More